TITLE

A varicella-zoster virus vaccine reduced the burden of illness of herpes zoster in older adults

PUB. DATE
November 2005
SOURCE
ACP Journal Club;Nov/Dec2005, Vol. 143 Issue 3, p61
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This article presents information on a clinical study according to which a varicella-zoster virus vaccine reduced the burden of illness of herpes zoster in older adults. 38,546 persons ≥ 60 years of age who had a history of varicella or had resided in the U.S. ≥ 30 years. Immunocompromised persons were excluded. Vaccine efficacy with respect to the severity of illness caused by herpes zoster, defined as the relative reduction in burden-of-illness score based on the severity and duration of herpes zoster pain and duration, comparing the vaccine and placebo groups. In persons ≥ 60 years of age, a live attenuated varicella-zoster virus vaccine decreased the burden of illness caused by herpes zoster and the incidence of postherpetic neuralgia.
ACCESSION #
18925729

 

Related Articles

  • A varicella-zoster virus vaccine reduced the burden of illness of herpes zoster in older adults: COMMENTARY. Fekete, Thomas // ACP Journal Club;Nov/Dec2005, Vol. 143 Issue 3, p61 

    This article comments on a clinical study according to which a varicella-zoster virus vaccine reduced the burden of illness of herpes zoster in older adults. The study may be the first to look at a vaccination strategy to prevent expression of a disease caused by reactivation of a latent...

  • Varicella zoster vaccine worth the cost?  // PharmacoEconomics & Outcomes News;10/7/2006, Issue 513, p5 

    The article discusses research on the cost effectiveness of a varicella zoster virus live vaccine, reference to a study by J. Hornberger and colleagues, published in the September 5, 2006 issue of the journal "Annals of Internal Medicine." The quality-adjusted life survival of patients who were...

  • Zoster Vaccine Live (Oka/Merck): A Viewpoint by Robert Johnson. Johnson, Robert // Drugs & Aging;2006, Vol. 23 Issue 6, p532 

    The article comments on the effectiveness of ZOSTAVAX® the Oka/Merck strain varicella zoster virus vaccine, in reducing the incidence of herpes zoster. The author stressed that herpes zoster is not a benign disease. The medical treatment for herpes zoster including hospitalization is poorly...

  • VARIVAX.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p2438 

    A definition of the term "VARIVAX," which refers to varicella virus vaccine live, is presented.

  • Zoster Vaccine Live (Oka/Merck): A Viewpoint by Anthony L. Cunningham. Cunningham, Anthony L. // Drugs & Aging;2006, Vol. 23 Issue 6, p532 

    The article comments on the effectiveness of ZOSTAVAX® the Oka/Merck strain varicella zoster virus vaccine, in reducing the incidence of herpes zoster. The author stressed that herpes zoster therapy significantly helped in reducing the incidence and the duration of severe pain. The...

  • Varicella Zoster Virus–Specific Immune Responses to a Herpes Zoster Vaccine in Elderly Recipients With Major Depression and the Impact of Antidepressant Medications. Irwin, Michael R.; Levin, Myron J.; Laudenslager, Mark L.; Olmstead, Richard; Lucko, Anne; Lang, Nancy; Carrillo, Carmen; Stanley, Harold A.; Caulfield, Michael J.; Weinberg, Adriana; Chan, Ivan S. F.; Clair, Jim; Smith, Jeff G.; Marchese, R. D.; Williams, Heather M.; Beck, Danielle J.; McCook, Patricia T.; Zhang, Jane H.; Johnson, Gary; Oxman, Michael N. // Clinical Infectious Diseases;Apr2013, Vol. 56 Issue 8, p1085 

    Depression diminishes varicella zoster virus cell-mediated immunity (VZV-CMI) responses to zoster vaccine, and antidepressant treatment is associated with normalization of these responses. As higher levels of VZV-CMI correlate with lower risk of herpes zoster (HZ), untreated depression may...

  • Herpes zoster vax cost effective in older adults in Belgium?  // PharmacoEconomics & Outcomes News;1/7/2012, Issue 644, p6 

    The article discusses research study on the cost-effectiveness of the varicella zoster virus vaccine Zostavax against herpes zoster in adults aged over 60 years in Belgium. It references a study by J. Bilcke et al published in the November 24, 2011 issue of "Vaccine." The researchers have...

  • Varicella vaccine efficacy.  // Caribbean Health;Oct2001, Vol. 4 Issue 5, p31 

    The article offers information on the effectiveness of varicella vaccine as treatment for all susceptible people over the age of one year in the U.S. Based from a case-control study conducted in Connecticut, live attenuated varicella vaccine has shown efficacy in medicating all susceptible...

  • Nucleotide Sequences that Distinguish Oka Vaccine from Parental Oka and Other Varicella-Zoster... Argaw, Takele; Cohen, Jeffrey I.; Klutch, Michael; Lekstrom, Kristen; Yoshikawa, Tetsushi; Asano, Yoshizo; Krause, Philip R. // Journal of Infectious Diseases;3/1/2000, Vol. 181 Issue 3, p1153 

    Identifies nucleotide sequences that distinguish Oka vaccine from parental Oka and other varicella-zoster virus isolates. Predicted difference in amino acid sequences; Stability of nucleotide changes identified in Oka vaccine viruses after passage in human subjects; Factors attributing to the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics